Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 1, 2022
Discovery & Translation

T cell aneuploidy after CRISPR TRAC editing; plus Poseida, Cellectis and more

BioCentury’s roundup of translational news
BioCentury | Jun 17, 2022
Emerging Company Profile

BlueSphere: TCR discovery at scale

Sole investor and integrated health system UPMC brings a client’s perspective on the Pitt spinout’s TCR cell therapies
BioCentury | Dec 18, 2021
Discovery & Translation

Regeneron’s humanized mice for therapeutic TCR discovery; plus Pattern, Century and more

BioCentury’s roundup of translational news
BioCentury | Jun 29, 2018
Product R&D

Highly personal

Why GV and Canaan backed Pact Pharma’s hyperpersonalized cancer approach
BioCentury | Mar 23, 2017
Translation in Brief

Precision-engineered CARs

Trucking gene constructs to the TRAC locus for better CAR T cells
BioCentury | Mar 21, 2017
Distillery Therapeutics

Cancer

BioCentury | Apr 21, 2014
Product Development

CAR hits pothole

Sloan Kettering's pause with CAR T cell therapy hasn't affected Juno partners
Items per page:
1 - 7 of 7